RAS Amplification as a Negative Predictor of Benefit from Anti‐EGFR–Containing Therapy Regimens in Metastatic Colorectal Cancer

BACKGROUND: RAS short variant (SV) mutations in colorectal cancer (CRC) are associated with lack of benefit from epidermal growth factor receptor (EGFR) monoclonal antibody (EGFRmAb). However, the clinical implications for RAS amplification (RASa) as a biomarker for anti‐EGFR therapy in CRC remain i...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncologist
Autori principali: Schrock, Alexa B., Lee, Jessica K., Sandhu, Jaideep, Madison, Russell, Cho‐Phan, Cheryl, Snider, Jeremy W., Castellanos, Emily, Venstrom, Jeffrey M., Fakih, Marwan
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons, Inc. 2021
Soggetti:
Gastrointestinal Cancer
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC8176984/
https://ncbi.nlm.nih.gov/pubmed/33465286
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/onco.13679
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi